In a new practice advisory, an international team of experts discussed the use of gadolinium-based contrast agents (GBCAs), an alternative to iodinated contrast media, in interventional pain ...
Mayo Clinic research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. The findings were ...
Mayo Clinic research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. The findings were ...
Approval expands low-dose MRI contrast options for the youngest patients and reflects a positive benefit–risk profile of VUEWAY® injection from birth through adulthood PRINCETON, N.J., Feb. 23, 2026 ...
June 9, 2006 — The U.S. Food and Drug Administration (FDA) has notified healthcare professionals regarding the potential risk for nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent ...
CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...
PRINCETON, N.J., Feb. 20, 2026 /PRNewswire/ -- Guerbet, a global specialist in contrast media and solutions for medical imaging, is pleased to announce that the U.S. Food and Drug Administration (FDA) ...
New research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. "Despite evidence that trace ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results